Objectives: Enhanced matrix metalloproteinase-8 (MMP-8) activity in the early post-myocardial infarction (MI) period has been related to early remodeling. However, it has been demonstrated that plasma MMP-8 level has a biphasic profile, and the relation between the late plasma levels and remodeling is unclear. We evaluated the plasma MMP-8 levels and its correlates 20±3 months after acute MI.
L eft ventricular (LV) myocardial remodeling is an important process in the development of heart failure in post-myocardial infarction (MI) patients. The rate and extent of cardiac remodeling have been proven to be independent predictors of morbidity and mortality. This process encompasses a complex and dynamic interaction of extracellular matrix (ECM) components, neurohormonal factors and myocytes. [1] Alterations within the ECM network cause loss of structural support exposing the cardiomyocytes to abnormal stress patterns, resulting in changes in LV geometry and myocardial dysfunction. [2] The matrix metalloproteinases (MMPs) are zinc-dependent proteolytic enzymes that have an important role in the modulation of the ECM and in the progression of LV remodeling both in the early and late post-MI period. [3, 4] Among MMP types, MMP-8 and MMP-9 exhibit significantly higher levels in the early post-MI period. Increased early levels of these two MMPs have been associated with early remodeling and even infarct rupture. [5, 6] However, these MMPs may have a biphasic plasma profile. [5] This biphasic profile, rather than the absolute level of MMP activity, may be important for LV remodeling. It was previously demonstrated that despite the relation between the early high levels and the extent of remodeling, higher plateau plasma MMP-9 levels were associated with relative preservation of LV systolic function. [5] We hypothesized that there may be a similar relationship between the late plasma MMP-8 levels and relative preservation of left ventricular ejection fraction (LVEF). Thus, we evaluated the plasma MMP-8 levels and its correlates at 20±3 months' post-MI.
PATIENTS AND METHODS

Study population
Seventy-nine patients with a history of a prior MI and revascularization (range: 390-810 days) were included in the study. Thirty-eight patients (65.5%) had undergone primary percutaneous coronary intervention and 20 patients (34.5%) had undergone coronary artery bypass graft (CABG) surgery. The presence of an infarct area was confirmed in all patients by singlephoton emission computed tomography (SPECT). Thirty-two age-matched controls had normal scintigraphic findings, except for intermediate lesions in their coronary angiograms. The exclusion criteria were a history of recurrent MI, presence of an active infection, peripheral arterial disease, aortic aneurysm, malignancy, chronic inflammatory disease, uncontrolled hypertension (>140/90 mmHg), LV hypertrophy (>1.2 cm) on echocardiogram, and renal and hepatic failure. Thus, six patients with uncontrolled hypertension, four with LV hypertrophy, one with reduced glomerular filtration rate, and two with an active infection were initially excluded from the study. Afterwards, an additional eight patients were excluded from the study due to the conditions that were neither diagnosed nor declared (2 with Behçet's disease, 1 with familial Mediterranean fever, 2 with peripheral arterial disease, and 3 with urinary tract infection). Of the control group, four with active infections and two with newly diagnosed uncontrolled hypertension were also excluded.
The investigation complies with the principles outlined in the Declaration of Helsinki. The study protocol was reviewed and approved by the local ethics committee. All subjects gave written informed consent that their blood samples could be used for scientific purposes.
Echocardiography
All echocardiograms were performed by two experienced sonographers using a Vivid 3 with a 2.5-3.5 MHz transducer (GE, Vingmed Ultrasound, Horten, Norway). Measurements were made according to the criteria defined by the American Society of Echocardiography. [8] Two-dimensional echocardiographic studies of the left ventricle included parasternal longand short-axis, apical four-and two-chamber views, and two-dimensionally derived M-mode images from the parasternal long axis. Doppler echocardiographic mitral valve inflow velocities were recorded from the apical four-chamber view with a cursor at the tips of the mitral valve leaflets with measurements of E wave velocity, A wave velocity and E wave deceleration time. Tissue Doppler velocities were recorded from both the septal and the lateral mitral annulus. Enddiastolic volume (EDV), end-systolic volume (ESV) and LVEF were estimated using the bi-planar modified Simpson's method from apical two-and four- 
Quantitative SPECT analysis
Treadmill exercise was the first-choice test modality. Patients unable to exercise adequately and those with left bundle branch block underwent pharmacologic stress. Exercise test was performed according to the Bruce protocol. Beta blockers, calcium antagonists and nitrates were discontinued at least 48 hours before testing. The pharmacological test was performed with intravenous dipyridamole infusion at 0.56 mg/kg dose over four minutes. Patients underwent rest and stress Tc-99m-sestamibi gated SPECT studies, 45-60 minutes after injection of 10 mCi and 25-30 mCi of Tc-99m-sestamibi, respectively. Images were obtained in the supine position with a rotating γ camera equipped with low-energy, high-resolution collimators. Myocardial perfusion quantitative analysis was performed using a commercially available software. The activity of each of the 17 sectors was expressed as the mean activity of all pixels belonging to this sector divided by the highest value of pixel activity in the myocardium. Infarct size was defined as the percentage of the left ventricle with pixel activities <60%. The EDV and ESV of the left ventricle and LVEF were also calculated. The images were rated by an experienced blinded nuclear medicine physician. 
Plasma MMP-8 measurements
After an overnight fasting, blood samples were collected into heparinized tubes and were centrifuged. Plasma was separated, aliquotted, and frozen at -80 °C until analysis. Total MMP-8 concentrations were measured using enzyme-linked immunosorbent assay (R&D Systems Inc, Minneapolis, MN) according to the manufacturer's instructions with 1:20 dilutions of the plasma. These are high sensitivity assay systems with a detection range of 0.01-0.06 ng/ml. All samples were analyzed in duplicate and averaged. The intra-assay coefficient of variation was 5.2%.
Statistical analysis
Continuous variables were tested for normality on the basis of tests of skewness and kurtosis. Depending on the distribution, continuous variables were presented as either mean±standard deviation or median with the corresponding interquartile range (IQR). Comparisons were made using either Student t-test or MannWhitney U-test. Categorical variables were presented as number and corresponding percentage. Differences between groups were assessed using the chi-square test. As the levels were not normally distributed, Spearman's rank correlation coefficients were calculated, as a nonparametric test, for the relationships between plasma MMP-8 levels and echocardiographic and scintigraphic parameters. Two-sided tests were used throughout, and values of p<0.05 were considered statistically significant. The Statistical Package for the Social Sciences (SPSS) software package version 14.0 (SPSS, Chicago, IL, USA) was used for data analysis.
RESULTS
Baseline characteristics and plasma MMP-8 levels
The study consisted of 84 subjects (58 post-MI patients and 26 age-matched control subjects). The mean age was 58±10 years (range: 32-79 years). The mean time after acute MI was 598.5±91.9 days (range: 390-810 days). Among post-MI patients, 15 had stable angina and four had unstable angina. In 18 of these patients with angina, ischemia was detected by SPECT analysis. The main clinical, laboratory, scintigraphic, and echocardiographic data are presented in Table 1 .
Comparison of plasma MMP-8 levels according to the main clinical characteristics revealed that the only parameter that significantly alters the plasma MMP-8 a biphasic profile during MI. Although higher early MMP-8 activity leads to early and extensive LV remodeling, higher late levels may be associated with relative preservation of LVEF.
The MMPs are the proteolytic enzymes responsible for ECM degradation. [4] These enzymes have a pivotal role in both early and late ventricular remodeling. [7, 9, 10] Previous studies have suggested that the monitoring of plasma MMP levels after MI may provide important diagnostic and prognostic information with respect to LV remodeling. [2, 7, 11] Although plasma levels of MMPs are indirect measures of the local myocardial levels, it has been demonstrated that they reflect the relative protein abundance in the myocardium. [2, 12] The plasma levels of MMP-8 and MMP-9 are significantly high in the early post-MI period. [7] Increased early levels of MMP-8 and MMP-9 have been associated with early remodeling and infarct rupture. [5, 6] However, there is a specific temporal biphasic profile of MMP release after MI. This biphasic profile, rather than the absolute level of MMP activity, may be important for LV remodeling. Kelly et al. [5] demonstrated that despite the relation between the early high levels and the extent of remodeling, the higher plateau plasma MMP-9 level was associated with relative preservation of LV systolic function. This finding may also be valid for plasma MMP-8 levels. We found that plasma MMP-8 level was still higher in post-MI patients even 20 months after MI. This may indicate that cardiac remodeling is active even years after MI, and MMP-8 has an active role in this process. When we analyzed the post-MI patients in order to determine the correlates of MMP-8 levels, we found a positive correlation between late plasma MMP-8 levels and LVEF. Enhanced MMP activity soon after MI results in proteolysis, which in the early post-MI period, leads to matrix degradation, early remodeling and even myocardial rupture. [6, 13] However, later in the process, this same proteolytic activity allows infiltration of other cell types, which mediate wound healing. [14] Thus, the high levels in the late post-MI period may be related to a successful repair process and relative preservation of LVEF.
Selective MMP inhibition has been shown to reduce LV remodeling after MI in experimental models. [15] However, Spinale et al. [16] demonstrated that MMP inhibition conferred a beneficial effect on survival early post-MI, but that prolonged MMP inhibition was associated with higher mortality rates and adverse LV remodeling. Thus, there may be an optimal time window with respect to pharmacological interruption of MMP activity in the post-MI period, and increased MMP activity later in the process may be a requirement for healing. We found that the plasma MMP-8 levels tended to be higher in patients using aspirin, angiotensin converting enzyme (ACE) inhibitors and statin. Drug therapies including ACE inhibitors, [17, 18] statins, [19, 20] angiotensin II receptor antagonists, [21] and acetylsalicylic acid [22] have been suggested to regulate gelatinase activity. However, there are no data about the relationship between drug therapy and plasma MMP-8 levels. The response to these drugs may change over time in parallel to the changes in the remodeling process. Thus, some of the benefits from antiischemic medications appear to be caused by the improved healing process associated with the increased levels of MMPs in the later phases of remodeling. Further trials are warranted to clearly explain this issue.
There are several limitations to our study. First, the number of subjects was small. Second, the plasma MMP-8 levels may represent total levels released from both cardiac and noncardiac sources. Despite the exclusion criteria, some potential noncardiac sources such as inflammatory periodontal diseases could not be excluded. [23] Furthermore, the plasma levels of MMPs cannot provide information on proteolytic activity within the myocardium. However, the previous studies have suggested that the plasma levels are likely to reflect the local myocardial levels. [2, 12] We cannot comment regarding plasma levels of other MMP entities. Moreover, there is an interaction between MMPs and the tissue inhibitors of matrix metalloproteinases (TIMPs) and other mediators of inflammation such as C-reactive protein, cytokines, chemokines, and angiogenic factors. [24, 25] The interaction between plasma MMP-8 levels and these factors was beyond the scope of the present analysis; yet, it should be investigated further. The absence of brain natriuretic peptide (BNP) data for the cohort is another limitation. Furthermore, we obtained plasma samples at only one post-MI time point. Therefore, further studies with serial plasma measurements in the early and late post-MI period may be warranted.
In conclusion, plasma MMP-8 levels remain high for a long period in post-MI patients. Moreover, plasma MMP-8 levels late after MI correlated positively with LVEF. This study does not establish causality. However, it supports the notion that MMP-8 continues to play a pivotal role in LV remodeling late after MI. In contrast to the relation between higher early MMP-8 activity and the extent of cardiac remodeling, higher late levels may be associated with relative preservation of LVEF.
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